Moreover, a HGF/c-MET specific antagonist, NK4, has been found to inhibit markedly the fibroblast-induced invasion of cancer cells, both in vitro and in vivo, [92–94] although this has yet to be translated into the clinical setting. The gene discussed is HGF; the disease is cancer.